Stromal Cell-Derived Factor-1 alpha Human Recombinant produced in
E. coli is a non-glycosylated, Polypeptide chain containing 68 amino acids and having a molecular mass of 8 kDa. The SDF-1a is purified by proprietary chromatographic techniques.
Synonyms: SDF-1, CXCL12, Pre-B cell growth-stimulating factor, PBSF, hIRH, chemokine (C-X-C motif) ligand 12, SDF1, SDF1A, TPAR1, SCYB12, SDF-1a, TLSF-a.
Formulation: The protein was lyophilized from a concentrated (1 mg/ml) sterile solution containing no additives.
Physical Appearance: Sterile Filtered White lyophilized (freeze-dried) powder.
Purity: Greater than 98% as determined by: (a) Analysis by RP-HPLC. (b) Analysis by SDS-PAGE.
Source:Escherichia coli.Amino acid sequence: KPVSLSYRCP CRFFESHVAR ANVKHLKILN TPNCALQIVA RLKNNNRQVC IDPKLKWIQE YLEKALNK
Uniprot ACC number: P48061
Transportation method: Shipped at room temperature.
Stability: Lyophilized SDF-1a although stable at room temperature.erature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution CXCL12 should be stored at 4°C between 2-7 days and for future use below -18°C. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA).Please prevent freeze-thaw cycles.
Biological Activity: The specific activity as determined by its ability to chemoattract human peripheral T cells activated with PHA and IL-2 using a concentation of 20-80 ng/ml corresponding to a Specific Activity of 12,500-50,000 IU/mg.
Solubility: It is recommended to reconstitute the lyophilized Stromal Cell-Derived Factor-1a in sterile 18MΩ-cm H
2O not less than 100 µg/ml, which can then be further diluted to other aqueous solutions.
References: 1.Title: Stromal Cell-Derived Factor-1a Promotes Neuroprotection, Angiogenesis, and Mobilization/Homing of Bone Marrow- Derived Cells in Stroke Rats. Publication: THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS Copyright © 2008 by The American Society for Pharmacology and Experimental Therapeutics JPET 324:834–849, 2008. Vol. 324, No. 2 127746/3301181 Printed in U.S.A. Link: http://jpet.aspetjournals.org/content/324/2/834.full.pdf Application: Intracerebral administration of SDF-1 resulted in neuroprotection against neurotoxic insult, and it induced increased BM-derived cell targeting to the ischemic brain, thereby reducing the volume of cerebral infarction and improving neural plasticity.2.Title:MECHANISMS OF BIOMATERIAL MEDIATED FIBROTIC RESPONSES AND STRATEGIES TOIMPROVE TISSUE REACTIONS TO BIOMATERIAL IMPLANTS.Publication:THE UNIVERSITY OF TEXAS AT ARLINGTONMay 2010Link:http://dspace.uta.edu/bitstream/handle/10106/4918/Thevenot_uta_2502D_10646.pdf?sequence=1
Safety data sheet: Inquire at info@3hbiomedical.com